Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.41 USD | +3.24% | +19.17% | +211.98% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+211.98% | 855M | C- | ||
+55.70% | 59.34B | B- | ||
+42.95% | 40.24B | A | ||
-5.39% | 39.88B | B | ||
-5.56% | 28.55B | C | ||
+16.46% | 27.26B | B- | ||
-20.56% | 19.23B | B | ||
+33.03% | 12.61B | C+ | ||
+25.85% | 12.28B | B+ | ||
+2.72% | 12.49B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STOK Stock
- Ratings Stoke Therapeutics, Inc.